Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of the three anti-cancer drugs
carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor
growth in participants with non-small cell lung cancer. This study will also assess whether
it is safe to combine these drugs.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania